Oct 24, 2017 Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Learn More
Oct 17, 2017 Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors Learn More
Oct 12, 2017 Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering Learn More
Oct 10, 2017 Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market Learn More